Cytomegalovirus gastritis after treatment with rituximab

We present a case of gastric ulcer with bleeding following chemotherapy with rituximab for non-Hodgkin's lymphoma (NHL).

A 68-year-old woman presented with hematemesis and melena. One year ago she had been diagnosed as having diffuse large B-cell NHL (stage IE) of the nasal root. She was treated with three courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by radiation therapy at a dose of 40 Gy, resulting in complete remission of the NHL. However, the patient had a relapse, with evidence of NHL in the thyroid gland and the mediastinal lymph nodes. Two weeks before the patient had hematemesis, she had been administered the first cycle of a second course of R-CHOP. At presentation, her hemoglobin level was 5.2 g/dL, which was lower than 2 days earlier (7.9 mg/dL). An esophagogastroduodenoscopy revealed multiple, irregular-shaped ulcers, with clearly demarcated borders, in the body of the stomach (● Fig. 1a).

One ulcer had vessels visible at the base (● Fig. 1b), and a hemoclip was placed endoscopically. Histological examination of the biopsy specimens showed nuclear inclusions in the epithelial cells (● Fig. 2a) with positive immunostaining for cytomegalovirus (CMV) (● Fig. 2b).

Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal cells of B-cell lineage and has been proved to be effective in the treatment of B-cell NHL [1,2]. However, the use of rituximab is associated with the development of certain severe viral infections [3–5]. Cytomegalovirus gastritis should be considered in the differential diagnosis in patients with gastric ulcers who are receiving rituximab treatment.

Endoscopy_UCTN_Code_CCL_1AB_2AD_3AC

Fig. 1 Esophagogastroduodenoscopy showing: **a** multiple ulcers with sharply defined borders; and **b** blood vessels at the base.

Fig. 2 Histological image showing: **a** epithelial cells containing nuclear inclusions; and **b** positive immunostaining for cytomegalovirus.

Y. Hasegawa¹, A. Goto¹, S. Nishimura¹, Y. Sukawa¹, K. Fujii¹, K. Suzuki¹, K. Yonezawa¹, T. Abe¹, Y. Shinomura², Y. Yoshida³

¹ Department of Gastroenterology, Kushiro City General Hospital, Kushiro, Japan

² First Department of Internal Medicine, Sapporo Medical University, Sapporo, Japan

³ Department of Clinical Pathology, Kushiro City General Hospital, Kushiro, Japan

References

- 1 Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* 2005; 23: 4117–4126
- 2 Persky DO, Unger JM, Spier CM et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. *J Clin Oncol* 2008; 26: 2258–2263
- 3 Aksoy S, Harputluoglu H, Kilickap S et al. Rituximab-related viral infections in lymphoma patients. *Leuk Lymphoma* 2007; 48: 1307–1312

4 Lee MY, Chiou TJ, Hsiao LT et al. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation. *Ann Hematol* 2008; 87: 285–289

5 Vallet S, Tempescul A, Tran A et al. Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab. *Ann Hematol* 2005; 84: 545–547

Bibliography

DOI 10.1055/s-0029-1214855

Endoscopy 2009; 41: E199

© Georg Thieme Verlag KG Stuttgart · New York · ISSN 0013-726X

Corresponding author

A. Goto, MD

Department of Gastroenterology

Kushiro City General Hospital

1-12 Shunkodai

Kushiro 085-0822

Japan

Fax: 81-0154-414080

kh8939@kushiro-cgph.jp